1 Dood W,Erickson BK,Arend RC,et al.Radical surgical cytoreduction in the treatment of ovarian carcinosarcoma.Gynecol Oncol,2014,133:234-237. 2 Paulsson G,Anderson S,Sorbe B.A population-based series of ovarian carcinosarcomas with long-term follow-up.Anticancer Res,2013,33:1003-1008. 3 Boussios S,Karathanasi A,Zakynthinakis-Kyriakou N,et al.Ovarian carcinosarcoma:current developments and future perspectives.Crit Rev Oncol Hematol,2019,134:46-55. 4 陆怡,吴红阳,彭万仁,等.子宫多发恶性中胚叶混合瘤1例报道并文献复习.罕少疾病杂志,2011,18:40-43. 5 王海霞,赵俊红,解其贵,等.17例子宫恶性中胚叶混合瘤临床病例特征及PRA、PKB蛋白表达及其意义.中国癌症杂志,2008,18:740-743. 6 Jernigan AM,Fader AN,Nutter B,et al.Ovarian carcinosarcoma:effects of cytoreductive status and platinum-based chemotherapy on survival.Obstet Gynecol Int,2013,2013:490508. 7 Brackmann M,Stasenko M,Uppal S,et al.Comparison of first-line chemotherapy regimens for ovarian carcinosarcoma:a single institution case series and review of the literature.BMC Cancer,2018,18:172. 8 Yalcin I,Meydanli MM,Turan AT,et al.Carcinosarcoma of the ovary compared to ovarian high-grade serous carcinoma:impact of optimal cytoreduction and standard adjuvant treatment.Int J Clin Oncol,2018,23:329-337. 9 Sherr CJ,McCormick F.The RB and p53 pathways in cancer.Cancer Cell,2002,2:103-12. 10 Roy R,Chun J,Powell SN.BRCA1 and BRCA2:different roles in common pathway of genome protection.Nat Rev Cancer,2011,12:68-78. 11 Evans T,Matulonis U.PARP inhibitors in ovarian cancer:evidence,experience and clinical potential.Ther Adv Med Oncol,2017,9:253-267. 12 Kamel D,Gray C,Walia JS,et al.PARP inhibitor drugs in the treatment of breast,ovarian,prostste and pancreatic cancers:an update of clinical trials.Curr Drug Targets,2018,19:21-37. 13 Angyl E,Tands P.Development of PARP inhibitors in gynecological malignancies.Curr Prob Cancer,2017,41:273-286. 14 Moore K,Colombo N,Scambia G,et al.Maintenance Olaparib in Patients with newly diagnosed advanced ovarian cancer.NENGI J Med,2018,379:2495-2505. 15 Le DT,Durham JN,Smith KN,et al.Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade.Science,2017,357:409-413. 16 Rauh-ain JA,Diver EJ,Clemmer JT,et al.Carcinosarcoma of the ovary compared to papillary serous ovarian carcinoma:a SEER analysis.Gynecol Oncol,2013,131:46-51.
